English
Home > Products > 13553-79-2

China 13553-79-2 Factory

We purpose to understand high quality disfigurement with the output and supply the top service to domestic and overseas buyers wholeheartedly for 13553-79-2,CAS NO 13553-79-2,Rifamycin S API,Rifamycin S, We've been willing to provide you with the lowest selling price during the market place, greatest high quality and quite nice sales service.Welcome to do bussines with us,let's be double win.
13553-79-2, Our company offers the full range from pre-sales to after-sales service, from product development to audit the use of maintenance, based on strong technical strength, superior product performance, reasonable prices and perfect service, we are going to continue to develop, to supply the high-quality merchandise and services, and promote lasting cooperation with our customers, common development and create a better future.

Related Products

Hot Products

  • D-Cycloserine

    D-Cycloserine

    Product Name:D-Cycloserine
    Molecular Formula:C3H6N2O2
    Molecular Weight:102.09
    CAS Registry Number:68-41-7
  • 3-Aminoisoquinoline

    3-Aminoisoquinoline

    Product Name:3-Aminoisoquinoline
    Molecular Formula:C9H8N2
    Molecular Weight:144.17
    CAS Registry Number:25475-67-6
  • 1,2,3-Triacetyl-5-deoxy-D-ribose

    1,2,3-Triacetyl-5-deoxy-D-ribose

    Product Name:1,2,3-Triacetyl-5-deoxy-D-ribose
    Molecular Formula:C11H16O7
    Molecular Weight:260.24
    CAS Registry Number:62211-93-2
  • 2,3-Difluorobenzonitrile

    2,3-Difluorobenzonitrile

    Product Name:2,3-Difluorobenzonitrile
    Molecular Formula:C7H3F2N
    Molecular Weight:139.1
    CAS Registry Number:21524-39-0
  • 4-Chloropyridinium chloride

    4-Chloropyridinium chloride

    Product Name:4-Chloropyridinium chloride
    Molecular Formula:C5H5Cl2N
    Molecular Weight:150.01
    CAS Registry Number:7379-35-3
  • Ethyl trifluoropyruvate

    Ethyl trifluoropyruvate

    Product Name:Ethyl trifluoropyruvate
    Molecular Formula:C5H5F3O3
    Molecular Weight:170.09
    CAS Registry Number:13081-18-0
  • Related Blog
  • Reviews

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

  • Everything You Need To Know About Active Pharmaceutical Ingredients (API In Pharma)

    Sandoo, as a professional API manufactruer in China, we produces a wide range of active pharmaceutical ingredients which can be used in the production of medicines in different applications.

  • Development Trend of China's Pharmaceutical Intermediate Industry

    The rapid development of China's pharmaceutical intermediate industry is closely related to its national policies. Since 2016, China has issued clear documents to encourage small and medium-sized enterprises to develop new drugs, including chemical raw materials. At the same time, the structural upgrading of the pharmaceutical industry in developed countries has promoted the transfer of global related industrial chains and promoted China's chemical raw material drug supply chain. In addition, the increase in Chinese radiography technology has boosted product demand.

  • How is a drug produced?

    ​There are so many different drugs ,with different color /shape ( like capsule ,tablet or Infusion) and price . Here we would like to explain , what makes it so different? How is a drug produced?

  • Pharmaceutical Intermediates Manufacturers - Something You Need to Know About Pharma Intermediates Industry

    Pharmaceutical intermediates are actually chemical raw materials or chemical products that need to be used in the synthesis of drugs. Such chemical products...

  • Tofacitinib More Effective, Alone and in Combinations, than Non-biologic DMARDS

    Tofacitinib (marketed under the brand name Xeljanz) is an oral Janus kinase inhibitor currently approved for the treatment of RA. It was developed in a unique public-private partnership between the National Institutes of Health...

Related Search

CAS NO 13553-79-2

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept